Member Info for Moneymunch

The US and UK markets are awaiting a positive update from Genflow on their progress towards fast track accelerated human clinical trials....Summer holidays still in full flow with the main City players not back until 1st week of September and Academia even later...hopefully any news will be delivered when everyone is back for maximum impact...in the meantime I'm going to buy a few early doors tomorrow in anticipation. Gla :-)))

11 billion barrels of oil: Staggering figures show scale of hydrocarbons found by supermajors in Namibia’s red-hot Orange basin

Shell and TotalEnergies have also discovered 8.7 trillion cubic feet of gas in prolific play

21 August 2023

Shell and TotalEnergies have discovered at least 11 billion barrels of light oil and up to 8.7 trillion cubic feet of gas in Namibia’s prolific Orange basin over the last 18 months, according to top petroleum officials in the country.

African Energy Chamber: South Africa must use its natural resources to address energy poverty

NJ Ayuk, African Energy Chamber August 11, 2023

In a televised speech earlier this summer, South Africa’s Minister of Mineral Resources and Energy, Gwede Mantashe, pushed back strongly against environmental groups’ efforts to block oil and gas production in his country.

Gwede Mantashe, South Africa’s Minister of Mineral Resources and Energy (Source: African Energy Chamber)

Even before his speech, Mantashe has been an outspoken advocate for driving oil and gas production in South Africa, where several major discoveries have been made in recent years. Cumulative output for TotalEnergies' Brulpadda and Luiperd natural gas discoveries, when developed, are estimated to be 50,000 bpd of liquids and 125,000 boed. These discoveries represent huge opportunities for South Africa to strengthen its economy and build energy security.

https://www.worldoil.com/news/2023/8/11/african-energy-chamber-south-africa-must-use-its-natural-resources-to-address-energy-poverty/

Fill ya Boots....Upside trajectory from this bargain low in anticipation of news on several fronts. Gla :-)

Very encouraging for something similar for Tower's Walvis acerage, and a win win either way as 25% of GBP's main target , the Welwitchia deeps, lie withinTower's adjoining block.....which near enough gives Tower a free carry on any drill.. Gl :-)

14 August 2023

Global Petroleum Limited

Namibia Update - Approval for Global to enter next phase of Licence PEL 94 Namibia

Global (AIM: GBP) is pleased to announce that the Namibian Ministry of Mines and Energy ("Ministry") has given approval for the Company and its partners to proceed to the First Renewal Period ("FRP") of Walvis Basin licence PEL 94, with a duration of two years from September 2023 to September 2025.

The work commitment for the FRP is to acquire, process and interpret 2,000 kms of 3D seismic data (the "3D Seismic") - carried over from the current Initial Exploration Period ("IEP") and to drill a well contingent upon the results of interpretation of the 3D Seismic. The original well commitment for the FRP - as specified in the Petroleum Agreement for PEL 94 - was firm, rather than contingent.

In accordance with standard provisions in the Petroleum Agreement, the Company and its partners are obliged to issue a guarantee at the beginning of each main phase of the licence, including the FRP. The guarantee is linked to the specified minimum exploration expenditure ("MEE"), which is the firm work commitment for the FRP (the commitment cost of the 3D Seismic), with the precise quantum to be agreed between Global and the Ministry, and has previously been negotiated as a low percentage of the MEE.

Importantly, The Ministry has waived the usual requirement to relinquish 50% of the licence area at the end of the IEP. This means that Global and its partners have retained all of the prospectivity of the licence on entry to the FRP - notably both of the primary prospects, Marula and Welwitschia Deep, together with the leads which the Company has identified in the eastern part of the licence.

The Company regards the grant of the two year FRP term (rather than a further one year extension to the IEP as originally expected) - together with the waiver of the relinquishment requirement - to be a successful outcome. It is also expected to give a major boost to the Company's ongoing farmout campaign.

In the broader Namibian context, Global is in full agreement with the widely held industry view that the drilling in the Orange Basin by Shell and TotalEnergies to date strongly suggests that Namibia has become a world class petroleum province, in terms of scale of likely resources.

Peter Hill, Global Petroleum's CEO, commented:

"We are very pleased to enter the next phase of PEL 94 with the prospectivity intact and the flexibility which a two-year term gives to us and our partners. We would like to convey our thanks to the Ministry of Mines and Energy accordingly.

  0 0

 Fingers crossed Vera will have an update/results in time for the conference, to pave the way for accelerated human clinical trials. Gla :-)

"Hopefully, we’ll have the results soon"

......

Vera Gorbunova on Long-Lived Species

Sirtuins apparently benefit some species more than others.

May 9, 2023

I didn’t know that you were also working on gene therapies for SIRT6 activation. Do you have any preliminary results or insights?

Like I said, this is ongoing, so I don’t have a lot of results, but we’re exploring this using different models and targeting different organs. Hopefully, we’ll have the results soon, but just based on genetic models of SIRT6 overexpression, we expect to see a rejuvenating effect, because if we simply overexpress SIRT6, mice live longer.

It’s not an easily translatable system, but if we can deliver SIRT6 and even express it transiently, we hope to see improvement. I can share one type of results, which is in cell culture, not in animals. When we overexpress SIRT6 briefly in cultured human cells, we see epigenetic age going down.

https://www.lifespan.io/news/vera-gorbunova-on-long-lived-species/

......

4th April 2023

Genflow said it had reached several milestones, including the completion of a detailed application dossier for the chemistry, manufacturing, and controls (CMC) of its NASH treatment.

It will present the dossier to the Belgian regulatory authorities in early June, paving the way for accelerated clinical trials as there is currently no known medical treatment for NASH.

In collaboration with Dr Manlio Vinciguerra at the University of Liverpool, the drug developer said it has achieved a deeper understanding of the biochemical changes in NASH treatment using its centenarian SIRT6.

The research findings have been published in a peer-reviewed journal, and Genflow is exploring additional intellectual property (IP) opportunities.

It has also initiated in-vivo evaluations of its centenarian SIRT6 gene therapy in four different NASH mice models in partnership with the University of Liverpool, the University of Rochester, and the clinical research group, Physiogenex.

The studies, which have analysed over 700 mice, aim to understand the efficacy and safety of the drug candidate in animal models with NASH. The results will be crucial for seeking authorisation for clinical trials in humans.

 0

The 2023 Longevity Summit Dublin Conference has announced its first speakers – and tickets are now on sale!

The Summit is on a mission is to recognise emerging research developments to extend human healthspan by gathering together world leading scientists.

To that end, The Longevity Summit Dublin will be a showcase for the most up-to-date research and innovations in the longevity industry and feature keynote presentations by leading experts in the aging field.

This conference, which is running from 17th to 20th August 2023, will feature over 40 global pioneering scientists, researchers and investors, as well as high net-worth investors, all on the same stage and who are all focused on challenging the epidemic of chronic diseases.

Dublin 2023

The premier annual conference of LEV Foundation

Join us August 17th – 20th 2023

Join the   Global Longevity

and Rejuvenation community

in  Dublin.

Network with leading figures around the world, build relationships with the longevity science industry and community, and learn about the latest emerging research. Longevity Summit Dublin is a must see for all science enthusiasts and all health enthusiasts.

Key note speakers include Vera Gorbunova- University of Rochester.

https://longevitysummitdublin.com/

A Big Blue day ahead day ahead by the looks of it....On and UP!!! Gla :-)

Mrs Seller's long gone, Big news expected soon and Upward momentum from this rockbottom low in anticipation....Multi-bag potential for those invested. Gla :-)

Looking leaky...Big news imminent????

3 chunky buys just in, 2 x 100k plus and 1 x 200k.

Nice find Pie Chart, let's hope the Belguim Regulatory Approval to fast track human clinical trials is imminent, to coincide. Gl :-)

Big news from Belguim soon which could add significant value and significant sp re-rate. Gla ;-)

Nice, it certainly doesn't take too much to get thus moving with Mrs Seller out. Gla holders....plenty more UPside to come. :-)

First in human proof-of-concept Phase I/ II Trial in Werner Syndrome

Genflow Biosciences is on the fast track to become a top performing biotechnology longevity powerhouse. An aggressive clinical development plan is underway. A team of seasoned industry leaders leads with confidence knowing there is short-term milestone potential.

Leveraging major unmet needs within communities affected by issues related to ageing is a key factor for aligning with Genflow Biosciences.

First in human proof-of-concept phase I/II trial in Non-Alcoholic Steato Hepatitis (NASH) and Werner Syndrome in patients that will be conducted in Sardinia. We will apply to Orphan drug designation for this indication. Werner syndrome is a heritable human premature ageing disease. As a classical premature ageing disease, etiological exploration of WS can shed light on the mechanisms of normal human ageing and facilitate the development of interventional strategies to improve health span.

First in human proof-of-concept Phase I/ II Trial in NASH

NASH is a  liver disease that affect  an estimated 35 million people globally with an  increasing prevalence.  NASH is becoming one of the leading causes of chronic liver disease and liver transplant and remains a significant unmet medical need with no approved therapies.  The adipogenesis, anti-fibrotic and anti-tumoral effects discovered in our recent pre-clinical program make GF-1002 a promising candidate for the treatment of NASH. The choice of NASH as potential indication for GF-1002 allows Genflow to benefit of clear regulatory accelerated development pathway and a potential conditional fast track approval.

0

On an UP!!! This rockbottom bargain low will not last long from now on in, in anticipation!!! :-)

0  0 0

I reckon Mrs Seller's orderly departure is now done, and the UK aswell as the US market is now awaiting Regulatory Approval from the Belguim Authorities for accelerated human clinical trials , the dossier was presented in June on the back of April's Peer Review Pulication, and so big news could be close......along with a big re-rate with any luck......Gla :-)

Yep, but the peer reviewed submission towards Regulatory Approval to accelerate Human Clinical trials, and so a multi-bag in a blink on confirmation....expected very soon!!! Gla :-)

Https://pubmed.ncbi.nlm.nih.gov/36534275/